Tarrytown-based Regeneron would acquire 23andMe for $256 million under the deal that is pending approval by bankruptcy court and regulators. New York-based biotech giant Regeneron Pharmaceuticals ...
Regeneron Pharmaceuticals gets a buy rating today, agreeing with the Wall St consensus. Impressive are its drug discovery pipeline across several clinical segments, profit margins, and low Debt/Equity ...
New York-based biotech giant Regeneron Pharmaceuticals announced May 19 its plan to purchase the bankrupt genetic testing firm 23andMe in a $256 million deal that could include millions of Americans' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback